Skip to main content
    M

    Medpace Holdings Inc (MEDP)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $653.09
    +4.89 (+0.75%)

    Market Cap: $18.29B

    Last updated: Nov 17, 2026 at 4:23 PM ET

    Medpace Holdings Inc (MEDP) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Medpace Holdings (MEDP) has a market cap of $18.29B and an enterprise value of $17.59B. Revenue grew 20.35% over the last 12 months from the 12 months before. Its trailing P/E of 36.2x is above its 10-year median of 28.9x.

    Total Valuation

    Enterprise value is 3.86% below the market cap, as cash exceeds debt.

    Market Cap$18.29B
    Enterprise Value$17.59B
    Latest price (Nov 17, 2026)$653.09

    Key Dates

    The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 8, 2027 (expected)
    Last Earnings DateOct 21, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.83% in the quarter ended Sep 30, 2026 and shrank 5.14% a year over 2 years.

    Shares Outstanding27.94M
    Shares Change (YoY)-0.70%
    Shares Change (QoQ)-0.83%
    Share Count Growth (2Y CAGR)-5.14%

    Valuation Ratios

    Sales and book value multiples are 6.4x and 31.2x. Its year-end P/E ranged from 20.4x to 44.3x from 2017 to 2025.

    P/E Ratio36.2x
    Forward P/E35.1x
    P/S Ratio6.4x
    Forward P/S6.4x
    P/B Ratio31.2x
    P/FCF Ratio27.3x
    P/OCF Ratio25.3x
    PEG Ratio3.5

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 27.6x EBITDA and 26.3x free cash flow.

    EV / Earnings34.0x
    EV / Sales6.2x
    EV / EBITDA27.6x
    EV / FCF26.3x

    Price Statistics

    The stock is up 10.68% over 52 weeks and trades 3.35% above its 50-day average.

    Beta (1Y)0.69
    52-Week Change+10.68%
    1-Month Change+5.39%
    3-Month Change+7.37%
    6-Month Change+55.53%
    5-Year Change+187.80%
    10-Year Change+2146.76%
    Total Return (1Y)+10.68%
    Total Return (3Y CAGR)+33.57%
    Total Return (5Y CAGR)+23.63%
    Return vs SPY (1Y)-0.90%
    Max Drawdown (1Y)-36.61%
    Max Drawdown (3Y)-39.38%
    Sharpe Ratio (1Y)0.22
    Correlation with SPY (1Y)0.21
    50-Day Average$631.90
    200-Day Average$532.67
    52-Week Range$373.00 to $693.97
    RSI (14 Days)51.7
    Average Volume (20 Days)294.26K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.83x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio0.83x
    Quick Ratio0.83x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 88.53% over the last 12 months, against a 5-year average of 56.09%.

    Return on Equity (ROE)88.53%
    Return on Assets (ROA)22.49%
    ROE (5Y Average)56.09%
    ROA (5Y Average)17.65%
    ROIC (5Y Average)95.95%
    Asset Turnover1.40x
    Receivables Turnover6.38x

    Taxes

    Income tax took 17.41% of pretax income over the last 12 months.

    Income Tax (TTM)$109.17M
    Effective Tax Rate17.41%

    Scores

    MEDP has an Altman Z-Score of 8.12, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score8.12
    Altman Z ZoneSafe
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $2.84B over the last 12 months.

    Revenue$2.84B
    Revenue Growth (YoY)+20.35%
    Gross Profit$2.84B
    Operating Income$607.14M
    Pretax Income$626.99M
    Net Income$517.83M
    EBITDA$635.15M
    Reported EPS (TTM)$18.04

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 25.43% of the $2.30B in total assets.

    Cash and Equivalents$705.32M
    Total Debt$0
    Net Cash$705.32M
    Net Cash Per Share$25.24
    Working Capital-$251.10M
    Shareholder Equity$584.94M
    Book Value Per Share$20.94
    Tangible Book Value-$110.41M
    Total Assets$2.30B
    Total Liabilities$1.72B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $55.42M of capital spending, operating cash flow left $667.63M of free cash flow.

    Operating Cash Flow$723.05M
    Capital Expenditures$55.42M
    Free Cash Flow$667.63M
    FCF Per Share$23.87
    Depreciation and Amortization$27.33M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 21.39%, against a 5-year average of 19.33%.

    Gross Margin100.00%
    Operating Margin21.39%
    Pretax Margin22.09%
    Net Margin18.24%
    EBITDA Margin22.38%
    FCF Margin23.52%
    Operating Margin (5Y Average)19.33%
    Net Margin (5Y Average)16.94%

    Growth

    Revenue grew 20.12% a year over 3 years, and EPS 27.51% a year.

    Revenue Growth (3Y CAGR)+20.12%
    Revenue Growth (5Y CAGR)+22.27%
    EPS Growth (3Y CAGR)+27.51%
    EPS Growth (5Y CAGR)+30.97%
    FCF Growth (3Y CAGR)+24.76%
    FCF Growth (5Y CAGR)+24.57%
    Operating Income Growth (3Y CAGR)+24.28%
    Book Value Per Share Growth (2Y CAGR)-5.00%

    Revenue and profit by year

    Dividends and Yields

    MEDP does not pay a dividend. Its free cash flow yield is 3.66%.

    Earnings Yield2.76%
    FCF Yield3.66%
    Buyback Yield1.62%
    Shareholder Yield1.62%

    Peer Position

    Against 11 similar companies, MEDP has the 5th highest P/E.

    P/E Ratio36.2x vs 26.6x median
    P/S Ratio6.4x vs 4.4x median
    Revenue Growth (Trailing 4 Quarters, YoY)+20.35% vs +6.27% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 9.27% and EPS growth at 13.92% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+9.27%
    EPS Growth Forecast (2Y CAGR)+13.92%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MEDP

    What is MEDP's market cap?

    Medpace Holdings has a market cap of $18.29B. Its enterprise value, which adds debt and subtracts cash, is $17.59B.

    What is MEDP's P/E ratio?

    Medpace Holdings has a trailing P/E ratio of 36.2x and a forward P/E of 35.1x.

    How many shares of MEDP are outstanding?

    Medpace Holdings has 27.94M shares outstanding. The count is down 0.70% from a year earlier.

    Does MEDP pay a dividend?

    No. Medpace Holdings does not pay a dividend.

    How much debt does MEDP have?

    Medpace Holdings has $0 of total debt and $705.32M of cash and equivalents, a net cash position of $705.32M.